We found that USP28 knockdown or pharmacological inhibition downregulates NOTCH1 signaling in CRISPR/Cas9-modified HG3 and primary CLL cells, indicating an oncogenic driver function for USP28 in CLL. This evidence concerns the gene NOTCH1 and B-cell chronic lymphocytic leukemia.